Analyst firms · Raymond James · IFRX
Raymond James IFRX price target and rating history
InflaRx N.V. (IFRX) · Health Care
Raymond James rates InflaRx N.V. (IFRX) Strong Buy with a $9 price target, as of its latest action on May 13, 2026. It has published 5 rating actions on IFRX since August 2021, including 2 upgrades and 1 downgrade. Across 4 firms with a IFRX price target in the last 12 months, the median target is $6.50. Raymond James's $9 is 38% above that.
- Current rating
- Strong Buy
- Price target
- $9
- Median target, all firms
- $6.50
- Actions on IFRX
- 5
Raymond James price target on IFRX
Every Raymond James rating on IFRX
- May 13, 2026
- May 29, 2025
- Nov 8, 2021
- Oct 28, 2021
- Aug 6, 2021
How other firms rate IFRX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Needham | Buy | $8 | Sep 14, 2026 |
| Raymond James | Strong Buy | $9 | May 13, 2026 |
| Oppenheimer | Outperform | $5 | Apr 24, 2026 |
| Leerink Partners | Market Perform | $2 | Dec 3, 2025 |
Questions about Raymond James and IFRX
- What is Raymond James's price target for IFRX?
- Raymond James's latest stated price target for InflaRx N.V. (IFRX) is $9, from its action on May 13, 2026.
- What is Raymond James's rating on IFRX?
- Raymond James rates IFRX Strong Buy, a bullish rating, as of May 13, 2026.
- When did Raymond James last change its view on IFRX?
- On May 13, 2026, Raymond James upgrades to Strong Buy from Outperform, price target $9.
- How does Raymond James's IFRX target compare with other analysts?
- Across 4 firms with a IFRX price target in the last 12 months, the median target is $6.50. Raymond James's $9 is 38% above that.
All Raymond James ratingsIFRX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.